Trial Profile
Use of radium-223 in heavily pretreated patients with metastatic castration resistant prostate cancer (mCRPC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Aug 2015
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 17 Aug 2015 New trial record